How To Get A 1-On-1 With An Expert On SAGE-547

Slingshot Insights, a web community that connects investors with professional primary research tools and cost-shared expert interviews, will be conducting an expert call to talk about the trial success of SAGE Therapeutics Inc (NASDAQ: SAGE)’s SAGE-547 on Friday.

The call will take a look at the results and setup for SAGE-547’s trial for the treatment of postpartum depression (PPD), trying to answer a simple question: does the drug have a place in the PPD space?

Related Link: Importance Of Phase 2 Trials

According to Slingshot Insights, this call is an important instance to better understand the extent to which the phase 2 study met its primary endpoint, significantly reducing the depression symptoms while yielding no reported adverse effects. However, they added, while the P value was very strong, the number of patients in the study was quite low. So, how significant are these results?

“Speaking to an expert will help determine how prevalent a treatment this may become versus the current, commonly used methods to treat PPD,” the firm went on to explain.

Interested? Join the call.

Disclosure: Javier Hasse holds no interest in any of the securities or entities mentioned above.